Diagnostic performance of a combined TAP, TAM, CA125 and CA153 panel for stage I breast cancer in patients with unilateral nipple discharge
- 1Translational Medicine Research Center, The Fifth Clinical Medical College of Henan University of Chinese Medicine (Zhengzhou People's Hospital), Zhengzhou, Henan 450002, P.R. China
- 2Department of Western General Internal Medicine, Children's Hospital Affiliated to Zhengzhou University, Zhengzhou, Henan 450018, P.R. China
Abstract
Minimally invasive biomarkers that complement imaging may improve risk stratification in patients presenting with unilateral nipple discharge. The present study evaluated the diagnostic performance of tumor-abnormal protein (TAP), tumor-associated material (TAM), carbohydrate antigen 125 (CA125) and cancer antigen 153 (CA153) for breast cancer, individually and in combination, with a particular emphasis on stage I disease. The present retrospective single-center study included 104 untreated patients with breast cancer and unilateral nipple discharge, including 25 patients with stage I disease, and 99 healthy controls. TAP, TAM, CA125 and CA153 were measured using standardized laboratory assays. Group differences were assessed using parametric or non-parametric statistical tests as appropriate. Receiver operating characteristic analyses were performed for individual biomarkers, whereas a multivariable logistic regression model was used for the combined panel. Optimal cut-off values were determined by maximizing Youden's index. TAP and TAM levels were significantly higher across all breast cancer stages compared with healthy controls, whereas CA125 and CA153 showed weaker stage-specific differences. For comparing all breast cancer cases with controls, the area under the curve (AUC) values for TAP, TAM, CA125, CA153 and the combined model were 0.919, 0.862, 0.648, 0.607 and 0.963, respectively. For distinguishing stage I breast cancer from controls, the corresponding AUC values were 0.923, 0.891, 0.552, 0.531 and 0.959. Furthermore, the combined model achieved 92.0% sensitivity and 93.9% specificity for stage I disease. TAP and TAM biomarkers provided stronger diagnostic discrimination than conventional tumor antigens, and their integration with CA125 and CA153 improved diagnostic identification of early-stage breast cancer compared with single-biomarker assays. As such, the combined panel may serve as an adjunctive risk-stratification tool in symptomatic patients with breast cancer, although prospective validation against benign breast disease is required.
Related
- Effects of unilateral single-mode balance training compared to combined balance and plyometric training on soccer players’ interlimb asymmetry in static and dynamic balance performance
- Diagnostic Performance of Triglyceride-Glucose Body Mass Index (TyG-BMI), Fibrosis-4 Index (FIB-4), and Their Combined Model for Clinically Significant Liver Fibrosis in Type 2 Diabetes Mellitus
- Diagnostic performance and pathologic associations of the UroVysion assay in patients with upper tract lesions and negative urinary cytology: a large-scale real-world study of 1,256 patients.
- Diagnostic Performance of Corrected Carotid Flow Time for Assessing Fluid Responsiveness in Patients With Septic or Hypovolemic Shock: A Prospective Diagnostic Accuracy Study
- Diagnostic performance of lung ultrasound in patients with clinically suspected interstitial lung disease
BibTeX
@article{men2026diagnostic,
title = {{Diagnostic performance of a combined TAP, TAM, CA125 and CA153 panel for stage I breast cancer in patients with unilateral nipple discharge}},
author = {Yingli Men and Ruiting Feng and Beibei Ye and Yahui Hu and Ping Wang and Jizhi Zhao and Yang Zheng and Hui Wang and Yinsen Song and Cong Ding},
journal = {Oncology Letters},
year = {2026},
month = oct,
doi = {10.3892/ol.2026.15915},
url = {https://doi.org/10.3892/ol.2026.15915},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Diagnostic performance of a combined TAP, TAM, CA125 and CA153 panel for stage I breast cancer in patients with unilateral nipple discharge
AU - Yingli Men
AU - Ruiting Feng
AU - Beibei Ye
AU - Yahui Hu
AU - Ping Wang
AU - Jizhi Zhao
AU - Yang Zheng
AU - Hui Wang
AU - Yinsen Song
AU - Cong Ding
PY - 2026
DA - 2026/10/22
JO - Oncology Letters
DO - 10.3892/ol.2026.15915
UR - https://doi.org/10.3892/ol.2026.15915
AB - Minimally invasive biomarkers that complement imaging may improve risk stratification in patients presenting with unilateral nipple discharge. The present study evaluated the diagnostic performance of tumor-abnormal protein (TAP), tumor-associated material (TAM), carbohydrate antigen 125 (CA125) and cancer antigen 153 (CA153) for breast cancer, individually and in combination, with a particular emphasis on stage I disease. The present retrospective single-center study included 104 untreated patients with breast cancer and unilateral nipple discharge, including 25 patients with stage I disease, and 99 healthy controls. TAP, TAM, CA125 and CA153 were measured using standardized laboratory assays. Group differences were assessed using parametric or non-parametric statistical tests as appropriate. Receiver operating characteristic analyses were performed for individual biomarkers, whereas a multivariable logistic regression model was used for the combined panel. Optimal cut-off values were determined by maximizing Youden's index. TAP and TAM levels were significantly higher across all breast cancer stages compared with healthy controls, whereas CA125 and CA153 showed weaker stage-specific differences. For comparing all breast cancer cases with controls, the area under the curve (AUC) values for TAP, TAM, CA125, CA153 and the combined model were 0.919, 0.862, 0.648, 0.607 and 0.963, respectively. For distinguishing stage I breast cancer from controls, the corresponding AUC values were 0.923, 0.891, 0.552, 0.531 and 0.959. Furthermore, the combined model achieved 92.0% sensitivity and 93.9% specificity for stage I disease. TAP and TAM biomarkers provided stronger diagnostic discrimination than conventional tumor antigens, and their integration with CA125 and CA153 improved diagnostic identification of early-stage breast cancer compared with single-biomarker assays. As such, the combined panel may serve as an adjunctive risk-stratification tool in symptomatic patients with breast cancer, although prospective validation against benign breast disease is required.
SN - 1792-1074
SN - 1792-1082
ER -